中国2018-2019年和2019-2020年流感季流感疫苗疑似预防接种异常反应监测  

Surveillance for adverse events following immunization with influenza vaccine in China during the 2018-2019 and 2019-2020 influenza seasons

作　　者：任敏睿 李克莉[1] 李媛 樊春祥[1] 李燕[1] 张丽娜 宋祎凡[1] 曹雷[1] 余文周[1] 尹遵栋[1] Ren Minrui;Li Keli;Li Yuan;Fan Chunxiang;Li Yan;Zhang Lina;Song Yifan;Cao Lei;Yu Wenzhou;Yin Zundong(National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing 100050,China)

机构地区：[1]中国疾病预防控制中心免疫规划中心,北京100050

出　　处：《中国疫苗和免疫》2023年第2期197-203,共7页Chinese Journal of Vaccines and Immunization

基　　金：中国疾病预防控制中心公共卫生应急反应机制的运行(131031001000150001)。

摘　　要：目的分析中国流感疫苗(Influenza vaccine,InfV)疑似预防接种异常反应(Adverse events following immunization,AEFI)发生特征。方法通过中国疾病预防控制信息系统收集2018-2019年和2019-2020年流感季InfV接种数据及AEFI报告数据,描述性分析AEFI分布特征和报告发生率。结果两个流感季中国共报告12383例InfV AEFI,总报告发生率为41.04/10万,其中一般反应、异常反应分别为37.41/10万、2.19/10万。一般反应中高热、局部红肿(直径>2.5cm)、局部硬结(直径>2.5cm)报告发生率分别为18.28/10万、5.95/10万、1.85/10万;异常反应中过敏性皮疹、热性惊厥、血管性水肿报告发生率分别为1.51/10万、0.16/10万、0.16/10万。结论中国2018-2019年和2019-2020年流感季InfV不良反应报告水平在可接受范围内,应继续加强InfV AEFI监测,提高监测质量。Objective To analyze adverse events following immunization(AEFI)with influenza vaccine(InfV)in China.Methods We obtained InfV vaccination and AEFI data reported during the 2018-2019 and 2019-2020 influenza seasons from the China Information System for Disease Control and Prevention and conducted a descriptive analysis of characteristics and incidences of InfV AEFI.Results A total of 12383 InfV AEFI cases were reported during the two influenza seasons,yielding an overall reporting incidence of 41.04 cases per 100000 doses.Reporting incidences for common and rare reactions were 37.41 and 2.19 per 100000 doses,respectively.Incidences for severe fever,injection-site redness/swelling(>2.5cm in diameter),and injection-site induration(>2.5cm in diameter)were 18.28,5.95,and 1.85 per 100000 doses.Incidences for anaphylactic rash,febrile seizures,and angioedema were 1.51,0.16,and 0.16 per 100000 doses.Conclusions The reporting incidence of adverse reactions for InfV AEFI was acceptable during the 2018-2019 and 2019-2020 influenza seasons in China.We should continue to strengthen AEFI surveillance and improve reporting quality.

关 键 词：流感疫苗 疑似预防接种异常反应 监测 

分 类 号：R186[医药卫生—流行病学]